FPGEE for National Association of Boards of Pharmacy (NABP) Practice Exam 2026 - Free NABP Practice Questions and Study Guide

Initial doses in human clinical trials are often determined using the no observed adverse effect level (NOAEL) identified from animal studies, which is then adjusted to account for differences between species, sensitivities, and the goal of ensuring patient safety. The commonly accepted approach is to use a fraction of the no effect dose (NED) to determine the initial human dose.

The correct choice of 1/100 - 1/10 NED reflects this cautious approach. By starting at lower levels, such as 1/100 of the NED, researchers can monitor for any adverse reactions before increasing the dose, ensuring a safer environment for participants. This strategy helps to assess the drug's safety profile and pharmacokinetics while minimizing risks, which is particularly important during the early phases of clinical trials when the effects of a new drug are still largely unknown.

Other options may suggest starting doses that are too high relative to the established no effect levels from animal studies, which may increase the risk of adverse effects while not aligning closely with the recommended safety protocols in clinical trial design. Thus, using a fraction of the NED in the range of 1/100 to 1/10 ensures a balance between assessing efficacy and ensuring participant safety.